Raymond James Financial Inc. Acquires New Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Raymond James Financial Inc. acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 90,107 shares of the company's stock, valued at approximately $609,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth about $27,000. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. Colonial River Investments LLC bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $68,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $75,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.20.

Remove Ads

Recursion Pharmaceuticals Trading Up 27.7 %

RXRX traded up $1.25 during midday trading on Friday, reaching $5.76. 83,130,078 shares of the company were exchanged, compared to its average volume of 11,739,915. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $2.32 billion, a P/E ratio of -3.76 and a beta of 1.00. The stock's 50-day simple moving average is $6.83 and its 200 day simple moving average is $6.84. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.42) EPS. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.